Get the Stockscreener App
224.66
1.00%
-2.27
Jazz Pharmaceuticals Plc stock is traded at $224.66, with a volume of 1.91M.
It is down -1.00% in the last 24 hours and down -2.13% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$226.93
Open:
$227.47
24h Volume:
1.91M
Relative Volume:
2.04
Market Cap:
$14.11B
Revenue:
$4.44B
Net Income/Loss:
$29.49M
P/E Ratio:
-12,209.78
EPS:
-0.0184
Net Cash Flow:
$1.19B
1W Performance:
-4.87%
1M Performance:
-2.13%
6M Performance:
+35.34%
1Y Performance:
+107.56%
1-Day Range:
$220.74
$228.00
1-Week Range:
$220.74
$236.44
52-Week Range:
$105.00
$243.32
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
224.66 | 14.11B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Feb-27-26 | Initiated | Barclays | Overweight |
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback - simplywall.st
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - TradingView
Jazz Pharma announces late-stage trial setback for lung cancer therapy - MSN
A potential billion-dollar deal looks for new ways to beat back cancer - The Business Journals
Jazz and AbCellera sign deal for T-cell engagers in solid tumours - Pharmaceutical Technology
Jazz Pharmaceuticals PLC (JAZZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insider Sell: Mark Smith Sells Shares of Jazz Pharmaceuticals PL - GuruFocus
AbCellera (NASDAQ: ABCL) inks Jazz cancer antibody pact with $56M upfront, big milestones - Stock Titan
Jazz taps Abcellera in potential $4B antibody discovery deal - BioWorld News
Jazz Pharmaceuticals, AbCellera announce oncology deal - grafa.com
Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B - BioSpace
Jazz Pharmaceuticals, AbCellera partner on cancer antibodies By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals, AbCellera partner on cancer antibodies - Investing.com UK
Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid Tumors - Yahoo Finance
Jazz Pharmaceuticals plc And AbCellera Biologics Inc Announces Collaboration To Discover Next-Generation T-Cell Engaging Multispecific Antibodies - marketscreener.com
Jazz Pharmaceuticals, AbCellera Biologics to Collaborate on T-cell Engaging Multispecific Antibodies - marketscreener.com
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies - PR Newswire
Jazz Pharmaceuticals (JAZZ) Reveals Key Findings at SLEEP 2026 - GuruFocus
Jazz presents Xywav data on cardiometabolic effects at SLEEP 2026 - Investing.com
Jazz presents Xywav data on cardiometabolic effects at SLEEP 2026 By Investing.com - Investing.com Australia
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia - PR Newswire
Jazz Pharmaceuticals PLC (JAZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
[144] Jazz Pharmaceuticals plc SEC Filing - Stock Titan
JAZZ’s Zepzelca fails to meet primary goal in lung cancer study - MSN
How Investors Are Reacting To Jazz (JAZZ) Zepzelca Failing Phase 3 LAGOON Survival Endpoint - simplywall.st
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study - Yahoo Finance
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ) - Yahoo Finance
Jazz Pharmaceuticals plc (JAZZ): Investor Outlook with Strong Buy Ratings and 11% Potential Upside - DirectorsTalk Interviews
Jazz, AstraZeneca, Astellas: Foreign healthcare's strongest quant picks - MSN
Insider Sell: Neena Patil Sells Shares of Jazz Pharmaceuticals P - GuruFocus
Jazz Pharmaceuticals (JAZZ) Shares Decline After Zepzelca Trial Results - GuruFocus
[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity - Stock Titan
Jazz Pharmaceuticals lung cancer drug fails late-stage trial By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals (JAZZ) Reports Phase 3 Trial Results for Ze - GuruFocus
Jazz Pharmaceuticals' Zepzelca misses primary goal in Phase 3 LAGOON trial - grafa.com
Jazz Pharmaceuticals (JAZZ) Retreats 1.70% as Price Action Consolidates Near Key SupportVolume Breakout Ideas - newsline.com
Jazz Pharmaceuticals stock falls after lung cancer trial fails By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals lung cancer drug fails main trial goal - Reuters
Jazz Pharmaceuticals stock falls after lung cancer trial fails - Investing.com
Jazz Pharmaceuticals’ Zepzelca fails phase 3 lung cancer trial By Investing.com - Investing.com Australia
Jazz Pharmaceuticals’ Zepzelca fails phase 3 lung cancer trial - Investing.com
Jazz Pharma lung cancer drug fails in late-stage trial (JAZZ) - Seeking Alpha
Jazz Pharma's lung cancer drug fails late-stage trial - marketscreener.com
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer - PR Newswire
MIdWestOne Financial Group Inc. Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):